The US Commodity Futures Trading Commission asked a federal court on September 2 to throw out CME Group’s lawsuit over cryptocurrency perpetual contracts, arguing the exchange giant’s competitive disadvantage is its own choice — not the regulator’s fault. The fight decides who gets to offer one of the most popular crypto trading products in America, and under what rules.
By Raj Patel | September 3, 2026
The Hook: A Regulator Telling a Giant Exchange “You Could Have Done This Too”
CME Group filed its lawsuit in the US District Court for the District of Columbia on June 18, seeking to overturn the CFTC’s approval of Kalshi’s Bitcoin perpetual contract and a related agency policy statement. On September 2, the CFTC fired back with a motion to dismiss, and its core argument is blunt: CME lacks legal standing because it could list comparable perpetual contracts on its own exchange under the very policy it is challenging.
In plain English, the regulator is saying the world’s largest futures exchange is complaining about a race it chose not to enter. The CFTC characterized part of CME’s claimed competitive disadvantage as resulting from its own decision not to offer comparable products — a disadvantage it calls “self-inflicted.” A party cannot establish standing in federal court by declining to use the same regulatory opportunity available to its competitors, the agency argued.
On-Chain Evidence: The Numbers the CFTC Put on the Table
The regulator did not stop at theory — it pointed to CME’s own trading data. According to the CFTC, CME’s Bitcoin and Ether futures volumes in June and August exceeded their May levels, the month the Kalshi approval was issued. Those figures form part of the agency’s argument that CME has not shown a concrete competitive loss caused by the approval. CME may challenge that interpretation when it responds.
- May 29 — CFTC approves Kalshi’s BTCPERP contract on KalshiEX, a registered designated contract market
- June 18 — CME sues to vacate the approval and the supporting policy statement
- September 2 — CFTC files its motion to dismiss
- October 2 — deadline for CME to respond before the court considers dismissal
The CFTC also raised a second standing argument about redressability. Even if the court reclassified perpetual contracts as swaps, competing venues could still offer economically similar products. In other words, a ruling in CME’s favor would change the regulatory category without necessarily removing the competition CME claims is harming its business. The agency further argued that CME’s competitive interests do not fall within the “zone of interests” protected by the Commodity Exchange Act provisions cited in the lawsuit.
The Core Conflict: Are Perpetuals Futures or Swaps?
To understand why this matters, you need to know what a perpetual contract is. Unlike a traditional futures contract, which has a fixed expiration and settlement date, a perpetual contract gives traders continuing price exposure with no end date. Recurring funding payments — small transfers between buyers and sellers — keep the contract price aligned with the underlying asset. Perpetuals have long been among the most-traded crypto products, but mostly on offshore exchanges.
CME argues that the lack of an expiration date places perpetuals within the swap definition established under the Dodd-Frank Act. The CFTC disagrees, maintaining that a futures contract does not require a fixed expiration date under the Commodity Exchange Act or existing regulatory interpretations. The distinction is not academic: each classification carries different registration, trading and oversight requirements, and swaps rules would impose heavier costs on venues offering the products.
The CFTC reviewed Kalshi’s application under Regulation 40.3, which allows a designated contract market to request formal approval before listing a new product, and concluded the contract complied with requirements. CME has framed the dispute as a matter of regulatory consistency and investor protection. The CFTC’s motion frames it differently: a competitor trying to use litigation against products it could offer itself. The court has not ruled on the motion or on the underlying futures-versus-swaps question.
Market Implications: What This Means for US Traders
The CFTC’s approval of Kalshi’s Bitcoin perpetual opened a regulated US venue to a product that had largely lived offshore. For everyday traders, that is a genuine win: regulated perpetuals mean customer protections, transparent rules and no need to trust an offshore exchange with your funds. If CME’s lawsuit succeeds and perpetuals are reclassified as swaps, the compliance burden could rise and some venues might retreat — reducing choice and pushing activity back offshore.
There is also a competitive subplot worth watching. CME is a designated contract market itself and can seek permission to list perpetual futures through the same process Kalshi used. If the lawsuit fails, the pressure on CME to simply launch its own perpetual products — rather than litigate — will grow. For investors, more regulated venues offering the product means tighter spreads and better liquidity.
The Verdict
The CFTC’s dismissal motion is a strong opening salvo, but it is only round one. CME has until October 2 to respond, and standing fights can go either way in federal court. The deeper question — whether crypto perpetuals are futures or swaps — remains unresolved and will shape the US derivatives landscape for years. For now, regulated Bitcoin perpetuals remain live on KalshiEX, and American traders retain access to one of crypto’s most popular instruments inside the regulated perimeter. That, in itself, is the new status quo CME is trying to undo.
The cryptocurrency market remains highly volatile. This article is for informational purposes only and does not constitute financial advice.
CFTC basically told CME ‘skill issue’ in a court filing lmao. brutal but kinda deserved, they sat out perps for years
CFTC basically told CME you could have listed perps too, you just didnt. brutal but kind of correct?
the standing argument is weaker than it sounds. the kalshi approval hits their clearing volumes directly, courts have taken thinner competitive harm cases
Standing is genuinely the weak point of CME’s suit. ‘we chose not to launch the product, but blame the regulator for approving a rival’ is a tough sell to a judge.
@Yuki that was my read too. The June 18 filing reads more like a PR move ahead of their own perp launch than a serious legal challenge.
The standing argument is stronger than people think. CME sat out the Kalshi perp approval for three weeks before suing in June. Hard to claim injury from a race you never entered.
^ this. also if CME wins, every exchange that got cold feet can retroactively sue over approvals they disliked. floodgates
kalshi perps have thin liquidity compared to offshore venues anyway. CME fighting this hard over a product they could have shipped in 2023 is comedy
CME shipped FX futures decades late too and still won. courts move slower than product cycles, standing is the real fight here not liquidity
meanwhile retail keeps trading perps on offshore venues with zero US oversight while CME and the CFTC burn court time. cool system
funny how the motion to dismiss landed the day before the CLARITY calendar imploded. regulators feeling confident this week apparently